Mantle Cell Lymphoma Relapse: Navigating Next Steps and Treatment Options
Mantle Cell Lymphoma (MCL) frequently relapses despite initial response. Management of relapsed/refractory (R/R) MCL is highly individualized based on multiple clinical and personal factors.
Key Decision Factors
- Prior therapies received (BTK inhibitor, chemoimmunotherapy, transplant)
- Duration of prior remission (shorter remission suggests more aggressive biology)
- Patient age, fitness, and comorbidities
- Disease tempo (indolent vs. blastoid/pleomorphic variant)
- Genetic markers (TP53 mutation, complex karyotype = poorer prognosis)
- Patient goals and preferences
Treatment Options for Relapsed MCL
BTK Inhibitors (If Not Previously Used or After Chemoimmunotherapy)
- Ibrutinib (first-in-class): Approved for R/R MCL; ~68% overall response rate (ORR)
- Acalabrutinib (second-gen): Better cardiac safety profile
- Zanubrutinib (second-gen): High CNS penetration; favorable safety
- Pirtobrutinib (non-covalent): Active after covalent BTK inhibitor failure (~50% ORR)
BCL-2 Inhibition
- Venetoclax: Combined with BTKi or rituximab; promising in R/R settings
PI3K Inhibitors
- Idelalisib, Duvelisib, Copanlisib: Approved for R/R MCL; require monitoring for infection, colitis, hepatotoxicity
Immunotherapy
- CAR T-cell therapy (Brexucabtagene autoleucel): FDA-approved for R/R MCL; ~90% ORR, ~60% complete response; CRS/ICANS risks
- Bispecific antibodies (epcoritamab, glofitamab): Emerging off-trial access
Other Modalities
- Chemoimmunotherapy: Bendamustine-rituximab, R-CHOP, R-DHAP (if chemo-sensitive, long prior remission)
- Radiation: Consolidation for localized relapse; palliation
- Allogeneic Stem Cell Transplant: Curative potential; high transplant-related mortality; considered for fit patients with high-risk features
- Clinical Trials: Strongly encouraged; novel agents (BTK degraders, CDK9 inhibitors, novel immunotherapies)
Treatment Goals
- Disease control and symptom relief
- Quality of life preservation
- Deep responses (complete remission) when achievable
- Sequencing therapies to maximize longevity
Multidisciplinary discussion at a lymphoma center of excellence optimizes sequencing and access to novel therapies.
Lymphoma - Related Articles
- Lymph Node Medullary Cords: Composition and Function
- Swollen Lymph Nodes: Causes, Symptoms & When to See a Doctor
- Cutaneous Follicular Lymphoma (CFL): Symptoms, Causes & Treatment
- B Cell Lymphoma Treatments: Understanding Your Options
- Lymph Nodes: Anatomy, Cellular Architecture, and Immune Function
- Sentinel Lymph Node Biopsy: Critical Role in Cancer Staging and Treatment
- Lymphopenia: Causes, Consequences, and Clinical Workup
